Neomorph Closes $100M Series B With First Patient Dosed

A patient in a San Diego clinic received an injection of NEO-811 on April 13, 2026 — a molecule that should not work, according to decades of drug discovery doctrine. It is not a PROTAC, the bifunctional degrader that has dominated the undruggable protein conversation for years. It is a molecular glue: a smaller, more elegant chemical that tricks two proteins into binding together in a way nature never intended, forcing the targeted protein into the trash heap of the cell. This is not news in a press release sense. This is the moment when a technology stops being theoretical and starts being real. And Neomorph just closed $100 million to find out what happens next.

The fundraise itself is clean: Deerfield Management is leading, with Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital (the investment arm of Dana-Farber Cancer Institute) participating. But the lead investor and the structure matter less than who is in the room behind Neomorph's clinical program. Novo Nordisk, Biogen, and AbbVie each have partnership agreements with Neomorph spanning cardiometabolic disease, rare disease, neurology, oncology, and immunology. This is not a relationship where a pharma company buys one option on one target. This is signal that three massive drug manufacturers believe the underlying platform — the ability to engineer protein surfaces that chemically induce degradation of previously unreachable disease drivers — is differentiated enough to bet corporate capital on it. Deerfield's Cam Wheeler, who chairs Neomorph's board, made the framing explicit: "the confidence of leading global pharmaceutical companies... speaks to the versatility of this platform." In biotech speak, that translates to: we are not hedging our bets, and neither are they.

NEO-811 is a molecular glue designed to induce degradation of ARNT (also called HIF-1β), a protein central to the signaling pathway that drives clear cell renal cell carcinoma (ccRCC). The Phase 1/2 trial is open-label, evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. The patient dosed on April 13 is the first human to receive this class of drug targeting this specific mechanism in this cancer type. The trial is dose-escalating, which means the real clinical work is just beginning — safety windows, tolerability ceilings, and whether any anti-tumor signal emerges will shape everything that follows. Neomorph is using the $100 million capital raise to fund this trial to meaningful readout and advance a broader pipeline of degrader molecules against other targets the company claims have been considered undruggable.

What created the conditions for this financing right now is the convergence of three separate trend lines. First, the regulatory and scientific case for molecular glue degraders has solidified in the past three years. The mechanism is no longer theoretically sound — it is mechanistically validated in cellular and animal models. Second, and critically, the pharma partnership model has shifted. Companies like Novo Nordisk and Biogen do not sign multi-area deals with early-stage platforms unless they have internal confidence that the underlying technology scales beyond a single target. Third, capital markets have learned to value clinical-stage biotechs differently. The presence of Regeneron Ventures as a Series B lead is material — Regeneron does not take equity stakes this late in a company's funding progression without strategic line-of-sight to either acquisition or a major value inflection. The $100 million round is not venture capital betting on science fiction. It is venture capital and pharma validation betting on a molecule already in a patient.

Neomorph's positioning relative to its competitors is now materially stronger than it was on April 12. C4 Therapeutics, which has been pursuing the molecular glue space longer, has yet to announce a first-in-human trial readout and has faced some earlier setbacks in clinical development. Ikena Oncology, another competitor in the space, is earlier in clinical development. The fact that Neomorph has the first patient dosed in a Phase 1/2 trial with molecular glue technology as the sole mechanism of action is a clinical proof point that matters. If NEO-811 shows acceptable safety and any signal of anti-tumor activity in the next 12 to 18 months, the entire category's investment narrative accelerates. If it fails or shows tolerability problems that halt the trial, the entire space takes a credibility hit. There is no splitting the difference in clinical trials — outcomes either move the field forward or backward.

Here is what is actually happening: molecular glue degraders are graduating from promising-lab-technology to clinical-evidence technology, and Neomorph has captured first-mover clinical advantage in a space that has been theoretically underfunded relative to its potential. The size of the addressable target space — the company claims to have built "the world's largest proprietary molecular glue target space" spanning multiple novel degrons and E3 ubiquitin ligases — is the structural advantage that matters. PROTACs have been the dominant degrader modality because they are easier to engineer, but they are also more constrained by the physics of requiring a linker to connect target to ligase. Molecular glues are harder to discover but, once validated, potentially more drug-like and potentially targetable against a broader protein surface. Neomorph is betting the company on the thesis that the harder discovery path is worth it because the therapeutic surface is larger. The $100 million check, plus three major pharma partnerships, suggests the market is taking that bet seriously. Whether that bet pays off will be determined by what happens in the clinic over the next two years.

Watch for three things: First, the NEO-811 Phase 1/2 dose-escalation readout. Any data on safety, pharmacokinetics, or preliminary anti-tumor activity will move the competitive landscape instantly. A clean safety profile and even modest anti-tumor signal would be validation. Tolerability problems or lack of mechanism engagement would reset the entire undruggable protein narrative around PROTACs and bifunctional degraders. Second, watch for IND filings from Neomorph's pipeline beyond oncology — specifically in neurology (Biogen partnership) and cardiometabolic disease (Novo Nordisk partnership). These partnerships suggest internal confidence that the molecular glue platform scales beyond ARNT degradation, but they also suggest that pharma partners are not yet ready to formally codevelop. A formal IND announcement for a neurological target would signal that Novo Nordisk or Biogen is willing to move from partnership agreement to shared development risk. Third, watch for deal escalation. Regeneron Ventures does not take Series B equity without expectation of acquisition or major licensing deal. Any announcement of co-development, exclusive licensing, or acquisition interest from a major pharma player would confirm that the market value of molecular glue technology has just shifted upward.